Publications by authors named "Natalie Percival"
British Gynaecological Cancer Society (BGCS) cervical cancer guidelines: Recommendations for practice.
Eur J Obstet Gynecol Reprod Biol
January 2021
Article Synopsis
- Cervical cancer rates are decreasing in many countries, thanks to screening programs and immunization, with expectations of further reduction in the coming decades.
- This guideline focuses on managing invasive cervical cancer, detailing diagnosis, imaging (including new technologies), and treatment options like surgery for smaller tumors and (chemo)-radiation for advanced cases.
- It also covers fertility-sparing procedures, special cases (like cancer during pregnancy), long-term effects, and ways to improve patient quality of life.
The approval, in 2015, of the first poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi; olaparib, Lynparza) for platinum-sensitive relapsed high-grade ovarian cancer with either germline or somatic BRCA1/2 deleterious mutations is changing the way that BRCA1/2 testing services are offered to patients with ovarian cancer. Ovarian cancer patients are now being referred for BRCA1/2 genetic testing for treatment decisions, in addition to familial risk estimation, and irrespective of a family history of breast or ovarian cancer. Furthermore, testing of tumor samples to identify the estimated 3%-9% of patients with somatic BRCA1/2 mutations who, in addition to germline carriers, could benefit from PARPi therapy is also now being considered.
View Article and Find Full Text PDFPurpose: The PARP inhibitor, Olaparib, is approved for women with BRCA-mutated ovarian cancer. Therefore there is an urgent need to test patients and obtain results in time to influence treatment. Models of BRCA testing, such as the mainstreaming oncogenetic pathway, involving oncology health professionals are being used.
View Article and Find Full Text PDF